Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATION AGREEMENTCollaboration Agreement • August 7th, 2006 • Discovery Partners International Inc • Services-commercial physical & biological research • Massachusetts
THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into as of the 24th day of February, 2006 (the “Effective Date”), by and between Infinity Pharmaceuticals, Inc., a Delaware corporation having an office at 780 Memorial Drive, Cambridge, Massachusetts 02139 (“Infinity”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation having an office at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (“Novartis”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisk denote omissions. COLLABORATION AND OPTION AGREEMENT by and between Infinity Pharmaceuticals, Inc. and Novartis International Pharmaceutical Ltd....Collaboration and Option Agreement • August 7th, 2006 • Discovery Partners International Inc • Services-commercial physical & biological research • Delaware
This Agreement is made this 16th day of November, 2004 (the “Effective Date”) by and between Infinity Pharmaceuticals, Inc. (“Infinity”), a Delaware corporation with principal offices at 780 Memorial Drive, Cambridge, Massachusetts 02139, and Novartis International Pharmaceutical Ltd. (“Novartis”), a Bermuda corporation with principal offices at Hurst Holme, 12 Trott Road, Hamilton, HM LX, Bermuda. Infinity and Novartis are sometimes referred to herein individually as a “Party” and together as the “Parties.”
LICENSE AGREEMENT BY AND BETWEEN INFINITY PHARMACEUTICALS, INC. AND AMGEN INC.License Agreement • August 7th, 2006 • Discovery Partners International Inc • Services-commercial physical & biological research • New York
THIS LICENSE AGREEMENT (the “Agreement”) dated the 7th day of July, 2006 (the “Effective Date”) is by and between INFINITY PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 780 Memorial Drive, Cambridge, Massachusetts 02139 (“Infinity”), and AMGEN INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”).
COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN INFINITY PHARMACEUTICALS, INC. AND JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENTCollaboration and License Agreement • August 7th, 2006 • Discovery Partners International Inc • Services-commercial physical & biological research • New York
THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) dated the 22nd day of December, 2004 (the “Effective Date”) is by and between INFINITY PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 780 Memorial Drive, Cambridge, Massachusetts 02139 (“Infinity”), and JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, a division of JANSSEN PHARMACEUTICA N.V., a Belgian business corporation organized and existing under the laws of Belgium with registration number RPR 0403.834.160, VAT No. BE-403.834.160, and with registered office at B-2340 Beerse, Belgium, Turnhoutseweg 30 (“JJPRD”).
